An open-label randomized phase II study of two different dosing regimens of capecitabine in combination with intravenous docetaxel (Q3W) in patients with locally advanced and/or metastatic breast cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2009
At a glance
- Drugs Capecitabine; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 19 Jan 2006 New trial record.